Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664249 | 0.86 | FYN (0.41) | LMNAHTR1DHTR1AHTR7GRIN2B | |
| SCHEMBL4144409 | 0.86 | TSHR (0.38) | LMNAHTR1D | |
| SCHEMBL13102476 | 0.85 | LMNA (0.47) | LMNAHTR1DHTR1AHTR7GRIN2B | |
| SCHEMBL4137087 | 0.84 | HTR1D (0.41) | LMNAHTR1DHTR1AHTR7GRIN2B | |
| SCHEMBL4145105 | 0.83 | HRH3 (0.34) | LMNACREBBPHTR2AHTR2CHTR2B | |
| SCHEMBL4136422 | 0.83 | HTR1A (0.41) | LMNAHTR1DHTR1AHTR7GRIN2B | |
| SCHEMBL4136458 | 0.82 | HRH3 (0.45) | LMNAHTR1DHTR1AHTR7GRIN2B | |
| SCHEMBL4136016 | 0.82 | HTR1D (0.41) | LMNAHTR1DHTR1AHTR7GRIN2B | |
| SCHEMBL4141070 | 0.81 | HTR1A (0.41) | HTR1DHTR1AHTR7GRIN2BHTR2A | |
| SCHEMBL4142789 | 0.80 | HTR7 (0.41) | LMNAHTR1DHTR1AHTR7GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | LMNA 4576/4885HTR1D 25/4885HTR1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.